CureVac Netherlands (former Frame Tx)

CureVac Netherlands BV is dedicated to transforming the treatment of cancer by directing the immune system towards Frame neoantigens. We are developing cancer immunotherapies, that are designed based on the Frame neoantigens uniquely encoded by the genome of each patients tumor. CureVac Netherlands is part of CureVac AG: a global biopharmaceutical company researching and developing novel drugs based on the natural molecule Messenger RNA (mRNA) with the main goal to bring multiple best-in-class mRNA drugs to market. The basic principle is the use of this mRNA molecule as a data carrier for information the body needs to fight various diseases. CureVac AG has more than 900 passionate employees, with its headquarters located in Tubingen, Germany and offices in Amsterdam (NL), Frankfurt (Germany), Ottignies-Louvain-la-Neuve (Belgium) and Boston (USA). As Antigen Discovery and Validation Center, CureVac Netherlands focuses on developing innovative cancer immunotherapies and the design and...